🔎 Trials Near Me

Dachaigh › Aillse a' bhroilleach › Ohio

Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Ohio

Tha 80 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann an Ohio.

Bailtean ann an Ohio

Teacsa sgrùdaidh oifigeil (Beurla)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 45 gu 75 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06995898

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

  • The Ohio State University, Columbus
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06784193

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Cleveland Clinic - Oncology Department, Cleveland
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06760819

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • agus 44 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
  • Taylor Cancer Research Center, Maumee
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06369285

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Cleveland
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05867251

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

  • James Cancer Hospital and Solove Research Institute, Columbus
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06120283

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020), Cincinnati
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07060807

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • University of Cincinnati Medical Center, Cincinnati
  • University of Cincinnati Medical Center - West Chester Hospital, West Chester
A’ fastadhÌre 3
Aoisean 60 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06377852

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  • Gabrail Cancer Center, Canton
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07007559

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027), Cincinnati
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06966700

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • Cleveland Clinic, Cleveland
  • Local Institution - 0102, Columbus
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT06618287

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Cleveland Clinic, Cleveland
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07214532

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Cincinnati
  • Clinical Trial Site, Columbus
  • Clinical Trial Site, Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • Cleveland Clinic Akron General, Akron
  • Gabrail Cancer Center, Canton
  • University Hospitals Cleveland Medical Center, Cleveland
  • agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07174336

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07109726

Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer

  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland
A’ fastadh
Aoisean 18 gu 65 · Banairean · Air ùrachadh 15 Sult 2026 · NCT04362826

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Miami Valley Hospital South, Centerville
  • MetroHealth, Cleveland
  • Cleveland Clinic, Cleveland
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT06492616

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • University Hospital Cleveland Medical Center, Cleveland
  • Cleveland Clinic, Cleveland
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06253871

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  • Cleveland Clinic Foundation, Cleveland
  • The Mark H. Zangmeister Center-Mid Ohio Oncology/Hematology, Inc., Columbus
A’ fastadhÌre 1
Aoisean 18 gu 55 · Banairean · Air ùrachadh 9 Sult 2026 · NCT07310420

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • Miami Valley Hospital South, Centerville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT05386108

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The Ohio State University (OSU) Wexner Medical Center, Columbus
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT06400472

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • University of Cincinnati Medical Center, Cincinnati
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07287917

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • Hillcrest Hospital, Mayfield Heights
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06790693

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

  • University of Cincinnati Medical Center, Cincinnati
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT07211178

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • Gabrail Cancer & Research Center, Canton
  • Cleveland Clinic, Cleveland
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06072612

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Summa Health System - Akron Campus, Akron
  • Aultman Alliance Community Hospital, Alliance
  • OhioHealth O'Bleness Hospital, Athens
  • agus 39 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 60 · Banairean · Air ùrachadh 2 Sult 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • Cleveland Clinic, Cleveland
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07029399

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Cleveland Clinic Taussig Cancer Institute, Cleveland
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT06774963

ATEMPT 2.0: Adjuvant T-DM1 vs TH

  • Stefanie Spielman Comprehensive Breast Center, Columbus
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT04893109

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Ohio State University Comprehensive Cancer Center, Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT06500481

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
A’ fastadhÌre 2
Aoisean 19 agus nas sine · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06129747

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

  • Oncology Hematology Care, Cincinnati
A’ fastadhÌre 3
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT05232916

E-Mindfulness Approaches for Living After Breast Cancer

  • Indu and Raj Soin Medical Center, Beavercreek
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
  • agus 16 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 50 · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT06748222

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT05579366

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

  • Ohio State University Comprehensive Cancer Center, Columbus
A’ fastadhÌre 2Fàilte do shaor-thoilich fhallain
Aoisean 45 gu 74 · Banairean · Air ùrachadh 4 Lùna 2026 · NCT06195306

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

  • Case Western Reserve University, Cleveland
A’ fastadhÌre 2
Aoisean 18 gu 55 · Banairean · Air ùrachadh 27 Iuch 2026 · NCT06184750

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Nationwide Children's Hospital, Colombus
  • The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
  • Taylor Cancer Research Center, Maumee
A’ fastadhÌre 2
Aoisean 8 agus nas sine · Gach gnè · Air ùrachadh 27 Iuch 2026 · NCT05503797

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.